Regulators of ADAMs also play a fundamental role in the pathogenesis of AD, as the pro-inflammatory cytokine interleukin-1 can increase the activity of ADAM-17 and the formation of soluble APP in astrocytes and, at the same time, decrease the production of Aβ. This evidence concerns the gene APP and Alzheimer disease.